CEBPA
CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.
Overview
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB.
CIViC holds 15 clinical evidence items and 1 assertion across 4 variants, naming Tretinoin and OICR-9429. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes genetic literature 0.80, affected pathway 0.42, literature 0.99, genetic association 0.87, somatic mutation 0.92, animal model 0.58). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Acute Myeloid Leukaemia.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.
- 1 · What it is
CEBPA (CCAAT/enhancer-binding protein alpha) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Leukaemia, Myeloproliferative neoplasms and Acute myeloid leukaemia.
- 2 · What goes wrong in cancer
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta.
- 3 · How drugs use it
No product in this corpus aims at CEBPA yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:1833 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49715 (protein name, function text, keywords and locations (REST API)); CIViC gene CEBPA (15 evidence items, 1 assertions, 4 variants; diseases: Acute Myeloid Leukaemia, Acute Myeloid Leukaemia With Mutated CEBPA (GraphQL API, CC0)); Open Targets ENSG00000245848 (association with cancer (MONDO_0004992) 0.87; per-cancer scores at or above 0.5: acute myeloid leukaemia 0.85, myeloproliferative neoplasm 0.85, leukaemia 0.86 (GraphQL API, CC0)); IntOGen CEBPA (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor that coordinates proliferation arrest and the differentiation of myeloid progenitors, adipocytes, hepatocytes, and cells of the lung and the placenta. Binds directly to the consensus DNA sequence 5'-T[TG]NNGNAA[TG]-3' acting as an activator on distinct target genes. During early embryogenesis, plays essential and redundant functions with CEBPB. Essential for the transition from common myeloid progenitors (CMP) to granulocyte/monocyte progenitors (GMP). Critical for the proper development of the liver and the lung. Necessary for terminal adipocyte differentiation, is required for postnatal maintenance of systemic energy homeostasis and lipid storage. Location: Nucleus; Nucleus, nucleolus (UniProt). Locus 19q13.11 (HGNC).
- Leukaemia: Open Targets association 0.86 with leukaemia (MONDO_0005059)
- Myeloproliferative neoplasms: Open Targets association 0.85 with myeloproliferative neoplasm (MONDO_0020076)
- Acute myeloid leukaemia: Open Targets association 0.85 with acute myeloid leukaemia (MONDO_0018874); CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 15 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Acute Myeloid Leukaemia With Mutated CEBPA.
Latest papers
topQuery for this target: (TITLE:"CEBPA" OR ABSTRACT:"CEBPA" OR TITLE:"CCAAT enhancer binding protein alpha" OR ABSTRACT:"CCAAT enhancer binding protein alpha" OR TITLE:"CCAAT/enhancer-binding protein alpha" OR ABSTRACT:"CCAAT/enhancer-binding protein alpha" OR TITLE:"C/EBP-alpha" OR ABSTRACT:"C/EBP-alpha") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CEBPA, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetZRSR2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
- TargetCSF2RB
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
- TargetGATA1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
- TargetDDX41
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), CIViC, Acute myeloid leukaemia.
- TargetRTEL1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
- TargetSBDS
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, Open Targets Platform.
- TargetRAD21
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.
- TargetPRKCD
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute myeloid leukaemia, IntOGen.